Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 11/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992616 | 0.86 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CUSP1CRHR1 | |
| SCHEMBL20007553 | 0.83 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CUSP1CRHR1 | |
| SCHEMBL2396222 | 0.82 | USP19 (0.38) | KMT2AGAAALDH1A1MAPTBRD4 | |
| SCHEMBL15207591 | 0.81 | HTR7 (0.42) | HPGD | |
| SCHEMBL30468499 | 0.80 | USP1 (0.33) | USP1MEN1APAF1KMT2AGAA | |
| SCHEMBL21904458 | 0.80 | USP1 (0.33) | USP1MEN1APAF1KMT2AGAA | |
| SCHEMBL722905 | 0.79 | PDE4B (0.37) | BRD4 | |
| SCHEMBL21904257 | 0.76 | USP1 (0.37) | USP1 | |
| SCHEMBL31003742 | 0.75 | BMPR1A (0.34) | MAPTHDAC6NPC1 | |
| SCHEMBL29549850 | 0.75 | AVPR1A (0.32) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134683-A1 | Novel process for the preparation of intermediate compounds used in the treatment of migraine | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-06-27 | — | — | WO | claimed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250353860-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | BRISE PHARMACEUTICALS CO., LTD. (CN) | 2025-11-20 | — | — | US | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4516793-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | Brise Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| CN-114245797-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061692-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007016087-A2 | HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353860-A1 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | CALCR, CNR2, CALCRL | ADRA2A 377/4885ADRA2B 618/4885ADRA2C 749/4885 |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | ADRA2A 45/4885ADRA2B 39/4885ADRA2C 105/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | ADRA2A 47/4885ADRA2B 44/4885ADRA2C 86/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | ADRA2A 47/4885ADRA2B 44/4885ADRA2C 86/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | ADRA2A 29/4885ADRA2B 39/4885ADRA2C 64/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | ADRA2A 100/4885ADRA2B 146/4885ADRA2C 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.